CCR5 and congenital rubella syndrome: Here, we focus on the specific action of leukocidins and propose leukocidin ED (LukED) as a prototype target in CRS, given the ability of LukED to kill several immune cell types and the availability of numerous compounds that can block its interaction with CCR5.